
Agenus/LinkedIn
Jul 26, 2025, 12:09
Agenus Will Present Survival Plateaus For Metastatic Solid Tumors At ESMO25
Agenus shared a post on LinkedIn:
“We’re excited to share that four Agenus abstracts have been accepted for presentation at ESMO25 (Berlin, October 17–21), highlighting clinical progress with our botensilimab plus balstilimab immunotherapy programs.
The Highlight:
An oral presentation featuring emerging survival plateaus in 343 patients with refractory metastatic solid tumors across five tumor types.
Additional Presentations Include:
Investigator-sponsored studies in cervical cancer, MSS metastatic colorectal cancer, and non-melanoma skin cancers, underscoring the broad potential of our innovative combinations in difficult-to-treat cancers.
Save the dates and learn more.”
More posts featuring Agenus.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 26, 2025, 20:53
Jul 26, 2025, 20:13
Jul 26, 2025, 16:51
Jul 26, 2025, 16:40
Jul 26, 2025, 15:43